Systematic screening identifies dual PI3K and mTOR Inhibition as a conserved therapeutic vulnerability in osteosarcoma
- Gupte, A.
- Baker, E.
- Wan, S.
- Stewart, E.
- Loh, A.
- Shelat, A.
- Gould, C.
- Chalk, A.
- Taylor, S.
- Lackovic, K.
- Karlström, Å.
- Mutsaers, A.
- Desai, J.
- Madhamshettiwar, P.
- Zannettino, A.
- Burns, C.
- Huang, D.
- Dyer, M.
- Simpson, K.
- Walkley, C.
Publication date
January 2015
DOI Publisher
American Association for Cancer Research (AACR) ISSN
1078-0432 Journal
Clinical Cancer ResearchAbstract
Disclosure of Potential Conflicts of Interest J. Desai is a consultant/advisory board member for GlaxoSmithKline, Novartis, and Roche. No potential conflicts of interest were disclosed by the other authors.Abstract not availableAnkita Gupte, Emma K. Baker, Soo-San Wan, Elizabeth Stewart, Amos Loh, Anang A. Shelat, Cathryn M. Gould, Alistair M. Chalk, Scott Taylor, Kurt Lackovic, Åsa Karlstr, om, Anthony J. Mutsaers, Jayesh Desai, Piyush B. Madhamshettiwar, Andrew C.W. Zannettino, Chris Burns, David C.S. Huang, Michael A. Dyer, Kaylene J. Simpson, and Carl R.Walkle
Add to ORKG